Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.

BMC cancer - 8 Nov 2019

Pandy Jessa Gilda P, Balolong-Garcia Joanmarie C, Cruz-Ordinario Mel Valerie B, Que Frances Victoria F

Abstract excerpt

BACKGROUND: Triple negative breast cancer (TNBC) represents 15-20% of breast cancers. Due to its heterogeneity and high rates of relapse, there is a need to optimize treatment efficacy. Platinum chemotherapy is still controversial and currently not recommended as first-line treatment for TNBC. Recent studies have shown promising activity of this regimen. This study was done to evaluate the effect of platinum...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Bridged-Ring Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Neoadjuvant Therapy

Share to Organoplatinum Compounds

Share to Paclitaxel

Share to Taxoids

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 31703646
DOI: 10.1186/s12885-019-6253-5
PMCID: PMC6839096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.PMID 31703646Read ↗

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.Semantic proximity Read ↗

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read ↗

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

Triple Negative Breast Cancer Treatment Options and Limitations: Future OutlookSemantic proximity Read ↗

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read ↗

Advances in the systemic treatment of triple-negative breast cancer.Semantic proximity Read ↗

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read ↗

Triple negative breast cancer: looking for the missing link between biology and treatments.Semantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.